Alnylam Pharmaceuticals, Inc. vs TG Therapeutics, Inc.: SG&A Expense Trends

SG&A Expense Trends: Alnylam Pharmaceuticals vs. TG Therapeutics

In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of Alnylam Pharmaceuticals and TG Therapeutics from 2014 to 2023. Alnylam Pharmaceuticals has seen a significant upward trajectory in SG&A expenses, growing by approximately 1,700% over the decade. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, TG Therapeutics, while also increasing their SG&A expenses, has shown a more modest growth of around 400%. This difference highlights varying strategic approaches in managing operational costs. Notably, both companies experienced a peak in 2021, with Alnylam's expenses reaching nearly 620 million USD, while TG Therapeutics hit 152 million USD. These trends offer insights into how each company allocates resources to support their growth and market presence.